NCT05293678View on ClinicalTrials.gov

Safety and Tolerability of Regeneron Anti-SARS-CoV-2 Monoclonal Antibody/Ies in Adult Healthy Volunteers as Related to COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

January 26, 2023

Study Completion Date

January 26, 2023

Conditions
Healthy
Interventions
DRUG

REGN15160 (IV)

Administered in single intravenous (IV) dose

DRUG

Matching Placebo (IV)

Administered in single IV dose

DRUG

REGN15160 (SC)

Administered in single subcutaneous (SC) dose

DRUG

Matching Placebo (SC)

Administered in single SC dose

Trial Locations (1)

B-3000

Regeneron Study Site, Leuven

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY